Miao Gelan, Yang Yulian, Yang Xuelian, Chen Dexiu, Liu Li, Lei Xianying
Department of Critical Care Medicine, The Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan Province, 646000, China.
Department of Anesthesiology, The First Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan Province, 646000, China.
Heliyon. 2024 Oct 1;10(19):e38819. doi: 10.1016/j.heliyon.2024.e38819. eCollection 2024 Oct 15.
Tumor Protein Translationally-Controlled 1 () is a highly conserved gene found across eukaryotic species. The protein encoded by is ubiquitously expressed both intracellularly and extracellularly across various tissues, and its levels are influenced by various external factors. TPT1 interacts with several key proteins, including p53, MCL1, and immunoglobulins, highlighting its crucial role in cellular processes. The dysregulation of TPT1 expression has been documented in a wide range of diseases, indicating its potential as a valuable biomarker. Additionally, targeting TPT1 presents a promising approach for treating and preventing various conditions. This review will assess the potential of TPT1 as a biomarker and evaluate the effectiveness of current strategies designed to inhibit TPT1 in disease contexts.
肿瘤蛋白翻译调控1(TPT1)是一种在真核生物物种中高度保守的基因。TPT1编码的蛋白质在各种组织的细胞内和细胞外均普遍表达,其水平受多种外部因素影响。TPT1与几种关键蛋白相互作用,包括p53、MCL1和免疫球蛋白,突出了其在细胞过程中的关键作用。TPT1表达失调在多种疾病中已有记载,表明其作为有价值生物标志物的潜力。此外,靶向TPT1为治疗和预防各种病症提供了一种有前景的方法。本综述将评估TPT1作为生物标志物的潜力,并评估当前在疾病背景下抑制TPT1的策略的有效性。